The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin.
Anti-obesity drug Mounjaro is set to rack up global sales worth nearly £22bn a year by the end of the decade. But Donald ...
Zacks.com on MSN11h
How to Play NVO Stock After New Drug's Success in Obesity StudyNovo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...
Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback